Vera Therapeutics VERA Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$299.62M-96.9% | -$152.15M-58.5% | -$95.99M-7.8% | -$89.06M-173% | ||
| $468K+346% | $105K+400% | $21K+102% | -$846K-581% | ||
| $37.93M+82.3% | $20.8M+81.0% | $11.49M+29.3% | $8.89M+195% | ||
| $13.91M— | —— | -$873K— | —— | ||
| $14.44M— | —— | -$2.22M— | —— | ||
| —— | —— | —— | $8.18M— | ||
| $1.45M-29.8% | $2.06M-7.2% | $2.22M-2.1% | $2.27M— | ||
| -$1.48M+38.4% | -$2.41M+9.0% | -$2.65M-1.7% | -$2.6M— | ||
| —— | -$351K— | —— | $111K+118% | ||
| -$241.1M-79.0% | -$134.68M-46.1% | -$92.18M-36.4% | -$67.6M-185% | ||
| $630K-35.2% | $972K+1,443% | $63K+1.6% | $62K— | ||
| $194.29M+142% | -$463.35M— | —— | —— | ||
| —— | $13K— | —— | —— | ||
| $6.98M-48.0% | $13.41M+1,170% | $1.06M— | —— | ||
| $308.9M-49.1% | $606.67M+354% | $133.54M+31.0% | $101.93M+89.2% | ||
| $262.08M+458% | $46.97M+2,335% | $1.93M— | —— | ||
| $6.72M+1.0% | $6.65M— | —— | $895K+5,165% | ||
| —— | —— | —— | —— | ||
| —— | $810K— | —— | —— | ||
| -$1.48M+38.4% | -$2.41M+9.0% | -$2.65M-1.7% | -$2.6M— | ||
| —— | -$351K— | —— | $111K+118% | ||
| —— | —— | —— | $8.18M— | ||
| $1.45M-29.8% | $2.06M-7.2% | $2.22M-2.1% | $2.27M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $0— | $0-100% | $24.74M+24.9% | $19.82M+303% | ||
| $6.98M-48.0% | $13.41M+1,170% | $1.06M-49.3% | $2.08M— | ||
| —— | —— | —— | —— | ||
| -$1.48M+38.4% | -$2.41M+9.0% | -$2.65M-1.7% | -$2.6M— | ||
| $252K— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| -$241.73M-78.2% | -$135.65M-47.1% | -$92.24M-36.3% | -$67.66M-185% | ||
| -$241.73M-78.2% | -$135.65M-47.1% | -$92.24M-36.3% | -$67.66M-185% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Vera Therapeutics's cash flow data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.